Covid-19 crisis — initially with treatments to help lessen the risks from contracting the virus, and then ultimately with a vaccine.
The high pressure, enormous need, and global attention are leading companies to try new things on the fly. Just last week, Regeneron Pharmaceuticals Inc.
signed a pact with its erstwhile rival Roche Holding AG aimed at substantially boosting supplies of a potential treatment for Covid-19; it even made some monetary sacrifices to do so.
And that’s only the latest example. Much of what’s happening represents a war-time type response to a unique situation, and it may not be repeated.